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We studied zoonotic transmission of Chlamydophila 
psittaci in 39 breeding facilities for Psittaciformes (cocka-
toos, parrots, parakeets, lories) that frequently used antimi-
crobial drugs. Genotypes A or E/B were detected in 14.9% 
of humans at these facilities. Information on antimicrobial 
drug use in Psittaciformes and a C. psittaci vaccine are ur-
gently required.
C
hlamydophila psittaci, an obligate, intracellular, gram-
negative bacterium, has 7 known genotypes (A–F and 
E/B) (1), All genotypes can be transmitted to humans and 
cause psittacosis or parrot fever (2). Genotypes are distin-
guished by sequencing of the  outer membrane protein A 
(ompA) gene (3) or by a recently developed ompA geno-
type-speciﬁ  c real-time PCR (4). C. psittaci can infect 465 
avian species in 30 avian orders, with at least 153 species 
in the order Psittaciformes (5). From 1988 through 2003, a 
total of 935 human cases of psittacosis were reported to the 
US Centers for Disease Control and Prevention (6); most 
were related to contact with Psittaciformes. Currently, 
≈100 psittacosis cases are reported annually in the United 
States, and 1 person may die of this disease each year. The 
incidence of psittacosis in men seems to be increasing in 
industrialized countries and is related to importation of ex-
otic birds. Other cases may not be correctly diagnosed or 
reported.
The Study
We investigated zoonotic transmission of C.  psittaci 
in Belgian breeding facilities for Psittaciformes (cocka-
toos, parrots, parakeets, lories). Participants were recruited 
through the Belgian Society for Parakeet and Parrot Breed-
ers. Fifty breeding facilities received a sampling package 
by regular mail. The package contained a questionnaire 
designed to assess information on the pet bird owners’ pro-
fessional and nonprofessional activities, smoking habits, 
general health status, use of medication, allergies, clinical 
signs speciﬁ  cally related to psittacosis; on the birds’ origin, 
housing, feeding, breeding, health status, and medication; 
and on the presence of other bird species. The package also 
contained dacron-tipped swabs and instructions for fecal 
(cage ﬂ  oor) or pharyngeal sampling in birds or humans, re-
spectively. We provided transport medium (7) for isolation 
and DNA stabilization buffer (Roche, Brussels, Belgium) 
for PCR, to be added to swabs after sampling. 
Packages returned by express mail 1 day after sam-
pling were stored at –80°C until use. Sampling packages 
are convenient and safe for investigators. Forty-one (82%) 
of 50 breeding facilities returned the packages. Two pack-
ages were incomplete and therefore excluded, resulting 
in samples from 308 birds and 46 humans from 39 Psit-
taciforme breeding facilities for testing. We also obtained 
pharyngeal samples from a veterinary student who was in-
volved in another study at the same breeding facilities. This 
student was examined before our study and every month 
for 4 months. All humans were examined and provided in-
formed consent.
The ompA gene was detected in birds and humans 
by using a C. psittaci–speciﬁ  c nested PCR/enzyme im-
munoassay (EIA) (8). Viable C.  psittaci were detected 
by isolation in buffalo green monkey cells and direct im-
munoﬂ  uorescence staining (IMAGEN; Dakocytomation, 
Copenhagen, Denmark) (7). When zoonotic transmission 
occurred, the infection source was traced by using a geno-
type-speciﬁ  c real-time PCR (4) for specimens from birds 
and their owners.
Fifty-nine (19.2%) of 308 Psittaciformes were positive 
for C. psittaci in the nested PCR/EIA, and bacteria were 
isolated from 25 (42.3%) birds with PCR-positive results. 
Of 39 tested breeding facilities, 8 (20.5%) were positive 
in both the nested PCR/EIA and culture, and respiratory 
disease was present at all facilities. Five other breeding 
facilities showed only positive results for the nested PCR/
EIA. One of these facilities was currently treating birds 
with doxycycline, and the remaining 4 had recently used 
doxycycline, oxytetracycline, or enroﬂ  oxacin. Treatment 
was successful because viable C. psittaci were not detected 
at these 5 breeding facilities, and all their birds appeared 
healthy. A total of 13 (33.3%) of 39 C. psittaci–positive 
breeding facilities showed a signiﬁ  cant correlation between 
fecal excretion of viable chlamydia and respiratory dis-
ease (odds ratio 14.5, 95% conﬁ  dence interval 1.6–130.5, 
p<0.05). 
The remaining 26 breeding facilities with healthy birds 
had negative results for PCR and culture. Early infections 
may have been missed because fecal excretion occurs af-
ter primary bacterial replication in the respiratory tract and 
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septicemia. Moreover, fecal shedding occurs intermittently 
and healthy carrier birds might not excrete bacteria for >1 
year. Pharyngeal swabs would have been a better choice 
for testing but psittacine owners are reluctant to catch their 
birds because stress induces respiratory disease. Reactiva-
tion of a C. psittaci carrier status might be involved in this 
phenomenon.
Nested PCR/EIA detected C. psittaci DNA in 6 (13%) 
of 46 pet bird owners. All 6 owners obtained birds at differ-
ent breeding facilities, and all facilities had birds positive 
for C. psittaci by PCR and culture. The infected persons 
were 22, 24, 31, 38, 49, and 56 years of age (mean age of 
the pet bird owners was 46 years). Viable organisms were 
present in 4 of 6 persons with positive PCR results, and all 
4 (who were nonsmokers and had no allergies) had mild re-
spiratory illness (shortness of breath or rhinitis and cough-
ing). Although the study was conducted in the summer, 8 
(20%) of the remaining 40 C. psittaci–negative owners re-
ported rhinitis or coughing during the past 2 weeks, some 
(7.5%) with a sore throat. Thus, statistical conclusions on 
the relationship of viable chlamydophila in humans and re-
spiratory disease were not obtained. 
The 23-year-old veterinary student was negative for C. 
psittaci before the study. His ﬁ  rst pharyngeal specimen af-
ter he visited breeding facilities  was positive by both PCR 
and culture. He remained infected until 1 month after end-
ing his study but showed only mild respiratory illness.   
C. psittaci genotype A was found in 5 pet bird owners 
and the veterinary student; these persons had rhinitis and 
a cough. The strain isolated from the pet bird owner who 
reported continued shortness of breath was genotype E/B. 
Thus, in contrast to the recently published reports on hu-
man psittacosis and pet birds (9–11), severe clinical signs 
with pneumonia did not occur in these patients and none 
were treated. However, 10 (25.6%) of 39 bird owners men-
tioned in the questionnaire that they had pneumonia after 
keeping Psittaciformes as pets, which was higher than the 
yearly rate of 8/1,000 pneumonia cases in Belgium. It is 
likely that pet bird owners and veterinarians are regularly 
infected and protected against severe disease. However, 
whether they become carriers and the possible consequenc-
es of infection are unknown. Protective clothing, including 
air ﬁ  lter face masks, is recommended for preventing oc-
cupational disease.
Conclusions
In our study, 18 (46.2%) of 39 breeding facilities had 
treated their birds with tetracycline, doxycycline, or enro-
ﬂ  oxacin in the past year. Four (10.2%) of 39 also used tet-
racyclines prophylactically. Of these 18 facilities, 8 (44%) 
were positive for C. psittaci by nested PCR/EIA and 3 
(16.6%) were positive by culture. Because of the risk of 
developing drug-resistant strains, as described for Chla-
mydia suis (12,13), regular use of antimicrobial drugs must 
be avoided. Since there is no vaccine against psittacosis, 
pet bird owners frequently use tetracyclines for treatment 
or prevention of respiratory disease. These drugs are sold 
on the Internet without a prescription because a prescrip-
tion is not needed in every country. Before the advent of 
antimicrobial drug treatment, human mortality rates were 
15%–20%. Thus, a vaccine and information on sensible 
use of antimicrobial drugs in Psittaciformes are needed to 
prevent psittacosis in humans and development of drug-re-
sistant bacterial strains.
Acknowledgments
We thank L. Braeckman for providing the questionnaire.
This study was supported by the Federal Department of 
Health, Food Chain Safety and Environment, and COST Action 
855 (animal chlamydioses and the zoonotic implications).
Dr Vanrompay is a professor in the Faculty of Bioscience 
Engineering, Department of Molecular Biotechnology, Ghent 
University. Her primary research interests include Chlamydi-
aceae host-cell interactions, diagnosis, epidemiology, vaccine 
development, and animal models for studying protective immune 
responses after C. psittaci or C. trachomatis infections.
References
  1.   Geens T, Desplanques A, van Loock M, Bönner BM, Kaleta EF, 
Magnino S, et al. Sequencing of the Chlamydophila psittaci ompA 
gene reveals a new genotype, E/B, and the need for a rapid discrimi-
natory genotyping method. J Clin Microbiol. 2005;43:2456–61.
  2.   Andersen AA, Vanrompay D. Avian chlamydiosis (psittacosis, orni-
thosis). In: Saif YM, Barnes HJ, Fadly AM, Glisson JR, McDougald 
LR, Swayne DE, editors. Diseases of poultry, 11th ed. Ames (IA): 
Iowa State University Press; 2003. p. 863–79.
  3.   Vanrompay D, Butaye P, Sayada C, Ducatelle R, Haesebrouck F. 
Characterization of avian Chlamydia psittaci strains using omp1 re-
striction mapping and serovar-speciﬁ  c monoclonal antibodies. Res 
Microbiol. 1997;148:327–33.
  4.   Geens T, Dewitte A, Boon N, Vanrompay D. Development of a 
Chlamydophila psittaci species-speciﬁ  c and genotype-speciﬁ  c real-
time PCR. Vet Res. 2005;36:787–97.
    5.    Kaleta EF, Taday EM. Avian host range of Chlamydophila spp. 
based on isolation, antigen detection and serology. Avian Pathol. 
2003;32:435–62.
  6.   Smith KA, Bradley KK, Stobierski MG, Tengelsen LA. Compen-
dium of measures to control Chlamydophila psittaci (formerly Chla-
mydia psittaci) infection among humans (psittacosis) and pet birds. 
J Am Vet Med Assoc. 2005;226:532–9.
  7.   Vanrompay D, Ducatelle R, Haesebrouck F. Diagnosis of avian chla-
mydiosis: speciﬁ  city of the modiﬁ  ed Gimenez staining on smears 
and comparison of the sensitivity of isolation in eggs and three dif-
ferent cell cultures. Zentralbl Veterinarmed B. 1992;39:105–12.
  8.   Van Loock M, Verminnen K, Messmer TO, Volckaert G, Goddeeris 
BM, Vanrompay D. Use of a nested PCR-enzyme immunoassay 
with an internal control to detect Chlamydophila psittaci in turkeys. 
BMC Infect Dis. 2005;5:76.
  9.  Telfer BL, Moberley SA, Hort KP, Branley JM, Dwyer DF, Mus-
catello DJ, et al. Probable psittacosis outbreak linked to wild birds. 
Emerg Infect Dis. 2005;11:391–7.DISPATCHES
1110  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 7, July 2007
10.   Heddema ER, van Hannen EJ, Duim B, de Jongh BM, Kaan JA, van 
Kessel R, et al. An outbreak of psittacosis due to Chlamydophila 
psittaci genotype A in a veterinary teaching hospital. J Med Micro-
biol. 2006;55:1571–5.
11.   Kaibu H, Iidda K, Ueki S, Ehara H, Shimasaki Y, Watanabe S, et al. 
Psittacosis in all four members of a family in Nagasaki, Japan. Jpn J 
Infect Dis. 2006;59:349–50.
12.   Dugan J, Rockey DD, Jones L, Andersen AA. Tetracycline resis-
tance in Chlamydia suis mediated by genomic islands inserted 
into the chlamydial inv-like gene. Antimicrob Agents Chemother. 
2004;48:3989–95.
13.   Dugan J, Andersen AA, Rockey DD. Functional characterization of 
IScs605, an insertion element carried by tetracycline-resistant Chla-
mydia suis. Microbiology. 2007;153:71–9.
Address for correspondence: Daisy Vanrompay, Faculty of Bioscience 
Engineering, Department of Molecular Biotechnology, Ghent University, 
Coupure Links 653, 9000 Ghent, Belgium; email: daisy.vanrompay@
ugent.be